乳腺癌中KiSS-1与核因子-κBp50和基质金属蛋白酶9的表达之相互关系及其临床病理意义

目的 探讨KiSS-1、核因子(NF)-κBp50和基质金属蛋白酶9(MMP-9)在乳腺癌组织中的表达和相互关系及其临床病理意义.方法 应用免疫组织化学EliVision法检测152例标本(乳腺癌92例,乳腺增生30例,癌旁乳腺30例)和伴有癌转移的腋窝淋巴结54枚中KiSS-1、NF-κBp50及MMP-9蛋白表达情况.应用原位杂交方法检测50例乳腺癌组织、20例癌旁乳腺组织中KiSS-1mRNA的表达.应用CMIAS真彩图像分析仪对免疫组织化学和原位杂交结果进行积分吸光度(IA)值测定,并计算其平均IA值.结果 (1)与癌旁乳腺组织表达比较,KiSS-1基因在乳腺癌组织学分级Ⅰ～Ⅱ级中(13.59±6.24)明显高于Ⅲ级(9.53±4.57)、TNM分期高(Ⅰ～Ⅱ期12.35±6.15,Ⅲ～Ⅳ期7.53±4.93)、在淋巴结转移率高的乳腺癌中的表达减弱(9.61±5.25,无转移组为13.06±5.89)甚至缺失;其在淋巴结转移灶(3.47±1.59)中的表达(IA值)明显低于其相应的原发灶(10.02±3.80).乳腺癌组织中KiSS-1 mRNA表达(10.84±4.90)与KiSS-1蛋白表达(11.67±6.22)有较好的一致性.(2)NF-κBp50、MMP-9在乳腺癌组织中表达上调,其上调程度随着乳腺癌分化程度的降低、TNM分期的增加、淋巴结转移及瘤块增大而逐渐增高.结论 KiSS-1蛋白在乳腺癌分化程度低、淋巴结转移组中的表达下降,并分别与NF-κBp50、MMP-9蛋白表达呈负相关;NF-κBp50与MMP-9蛋白在乳腺癌中表达呈正相关,KiSS-1蛋白可能参与了乳腺癌的转移扩散.     

应用组织芯片研究基质金属蛋白酶-13在 乳腺癌中的表达及其临床意义

目的：探讨基质金属蛋白酶-13（matrix metalloproteinase-13, MMP-13）在乳腺癌发生、发展过程中的临床意义。方法：应用组织芯片技术和免疫组织化学SP法检测MMP-13在97例乳腺癌和39例乳腺纤维腺瘤中的表达情况,并分析其与临床病理参数的关系。结果：乳腺癌中MMP-13的表达（65.98%）显著高于乳腺纤维腺瘤（23.08%）,其表达与腋窝淋巴结转移、临床分期有关,而与患者年龄、肿瘤大小无关。结论：MMP-13与乳腺癌的发生、发展有着密切关系,可作为评估乳腺癌转移和预后的重要生物学指标。     

非小细胞肺癌组织中MMP-9、TIMP-1表达及意义

目的 探讨非小细胞肺癌(non-small cell lung cancer,NSCLC)组织中基质金属蛋白酶9(MMP-9)、组织金属蛋白酶抑制剂-1(TIMP-1)的表达及其生物学行为的关系.方法 应用免疫组织化学SP法检测76例NSCLC和癌旁正常组织中MMP-9、TIMP-1的表达,并分析其表达与肺癌组织类型、肿瘤大小、TNM分期、分化程度、淋巴结转移的相关性.结果 MMP-9、TIMP-1在肺癌组织中的阳性表达率明显高于癌旁正常组织(P<0.05).NSCLC中MMP-9、TIMP-1表达与肿瘤的分化程度、临床分期、淋巴结转移有相关性(P<0.05),与肿瘤病理分型无关(P>0.05).结论 检测NSCLC中组织的MMP-9、TIMP-1的表达对判断肿瘤的恶性程度和预后评估有一定的意义.     

浸润性乳腺癌中基质金属蛋白酶-13蛋白的表达及其与其他相关因子和预后的关系

目的 探讨浸润性乳腺癌中基质金属蛋白酶(MMP)-13蛋白在肿瘤细胞和间质细胞中的表达及其与肿瘤临床病理、生物学指标以及预后的相关性.方法 采用组织芯片免疫组织化学染色sP法检测263例浸润性乳腺癌组织中MMP-13、ER、PR、HER2、MMP-2、MMP-9、基质金属蛋白酶组织抑制因子(TIMP)-1、TIMP-2蛋白的表达及表达间的相关性.结果 MMP-13在肿瘤细胞及间质纤维母细胞中均表达,肿瘤细胞中MMP-13过表达与淋巴结受累和高组织学分级相关(均P<0.01),且与HER2表达(P=0.015)和肿瘤细胞TIMP-1蛋白表达相关(P<0.01).MMP-13过表达与患者总生存期缩短相关,分层分析显示MMP-13的过表达分别与淋巴结阳性患者总生存期和HER2阳性和阴性表达状态下的患者总生存期有关.间质纤维母细胞表达MMP-13尽管与肿瘤细胞表达者有相关性,且与淋巴结状态和HER2表达也相关,但评估预后的价值较弱.经单因素分析,肿瘤直径、组织学分级、淋巴结和PR、HER2表达状态及肿瘤表达的TIMP-1和MMP-13均是有意义的预后指标;但多因素分析显示仅肿瘤直径、组织学分级、淋巴结状态、HER2表达、肿瘤中TIMP-1和MMP-13表达是独立预后因素.结论 MMP-13蛋白与浸润性乳腺癌的侵袭和转移相关,有可能作为预后不良的指标.     

bFGF在恶性肿瘤中的表达及其临床病理意义

目的:检测临床常见恶性肿瘤(非小细胞肺癌、乳腺癌、结肠癌和黑色素瘤)组织中碱性成纤维细胞生长因子(b FGF)的表达情况,并分析其与恶性肿瘤临床病理学特征之间的相关性。方法:采用免疫组织化学SP技术检测208例原发性恶性肿瘤(肺癌68例,乳腺癌80例,结肠癌41例和黑色素瘤19例)石蜡包埋组织中b FGF蛋白的表达水平。结果:在肺癌中b FGF蛋白高表达多见于伴有淋巴结转移的低分化患者,与肿瘤原发灶大小、淋巴结受累、远处转移(TNM)分期呈正相关,且b FGF的表达对患者中位生存期无明显影响;在乳腺癌中,b FGF高表达多见于伴淋巴结转移的晚期患者;在结肠癌中b FGF蛋白表达多见于伴有区域淋巴结转移的中高分化患者;此外,在晚期有淋巴结转移的黑色素瘤患者中,b FGF蛋白呈高表达。结论:b FGF可能参与了临床常见恶性肿瘤的发生和演变过程,b FGF蛋白表达可能成为判断恶性肿瘤是否发生转移的有效参考指标之一。     

基质金属蛋白酶2和9及血管内皮生长因子C在乳腺癌淋巴结转移中的作用

目的 研究血管内皮生长因子C(VEGF-C)与基质金属蛋白酶(MMP)-2、MMP-9在乳腺癌组织中的表达及三者在乳腺癌淋巴结转移中的作用.方法 应用免疫组织化学SP法对84例乳腺癌(有腋淋巴结转移者52例,无腋淋巴结转移者32例)的VEGF-C、MMP-2和-9以及血管内皮透明质酸受体-1(LYVE-1)的表达进行检测,统计分析VEGF-C、MMP-2和-9与乳腺癌淋巴管生成的关系.利用重组质粒表达载体介导的短发夹式干扰RNA(shRNA)靶向沉默乳腺癌MCF-7细胞株中VEGF-C基因,PCR检测VEGF-C、MMP-2和-9的表达.结果 VEGF-C与MMP-2和-9在乳腺癌组织中均呈过表达,分别为83.3%(70/84)、89.3%(75/84)和75.0%(63/84),且在腋淋巴结转移组[94.2%(49/52)、98.1%(51/52)和88.5%(46/52)]比无淋巴结转移组[65.6%(21/32)、75.0%(24/32)和53.1%(17/32)]明显高表达(P＜0.05);淋巴管密度在腋淋巴结转移组及无转移组的表达有统计学意义(P＜0.05),随着VEGF-C与MMP-2和-9表达强度增加,淋巴管数量也增加(P＜0.05);转染重组质粒后MCF-7细胞株的VEGF-C及MMP-2和-9的mRNA表达水平下调,抑制率分别为95.0%、53.0%和77.0%(P＜0.05).结论 VEGF-C与MMP-2和-9协同促进乳腺癌组织的淋巴管新生和乳腺癌淋巴结转移.     

The c-erbB-2 Protein in Primary and Metastatic Breast Carcinomas

Material from 41 patients with primary breast carcinoma and lymph node metastases at the time of primary surgical intervention was immunostained for c-erbB-2 protein, neuron-specific enolase (NSE), and estrogen receptors. Thirty of the primary breast carcinomas were of ductal type. Six were classified as infiltrating lobular carcinomas, 2 were apocrine, 1 was mucinous, and 1 was a tubular carcinoma. One tumor could not be classified as ductal or lobular by light microscopic examination alone. The number of lymph node metastases available varied from 1 to 14 per case (median, 3.9). Nine (22%) of the primary breast carcinomas (8 ductal and 1 apocrine) expressed c-erbB-2 protein and showed c-erbB-2 gene amplification; 12 expressed NSE immunoreactivity. None expressed both markers. Estrogen receptor immunoreactivity was present in 23 of the 41 cases, including 9 of the NSE-positive cases. C-erbB-2 protein-positive metastases were present in 18 cases (44%), and in 13 cases all metastases were immunostained. In 5 cases the expression of c-erbB-2 protein varied from metastasis to metastasis. NSE immunoreactivity was expressed in 10 cases, and in 3 cases with minor NSE-positive cell populations the metastatic lesions expressed c-erbB-2 protein as well. All 9 primary breast carcinomas expressing c-erbB-2 protein had lymph node metastases with c-erbB-2-immunoreactive tumor cells. Eight of the 9 c-erbB-2 protein-negative primary tumors with metastases expressing c-erbB-2 protein showed no amplification of the c-erbB-2 gene. Thus expression of c-erbB-2 protein can occur during the metastatic process, even if it seems to be missing in the primary tumor. On the other hand, if a primary breast carcinoma expresses c-erbB-2 protein, this feature seems to be present in all the tumor metastases as well.     

CD147、基质金属蛋白酶和转化生长因子β1在乳腺癌中的表达与肿瘤转移和预后及其相互间的关系

目的 探讨CD147和基质金属蛋白酶(MMP)-2和MMP-9与转化生长因子(TGF)β1及其Ⅰ型受体(TGFβR I)在乳腺癌组织中的表达与肿瘤转移和预后及其相互间的关系.方法 建立组织芯片平台,应用免疫组织化学SP法检测160例乳腺癌组织CD147、MMP-2、MMP-9、TGFβ1和TGFβRI蛋白的表达情况,并进行了8～64个月随访.结果 160例乳腺癌中CD147、MMP-2、MMP-9、TGFβ1和TGFβRI阳性率分别为87.5%(140例)、96.9%(155例)、95.0%(152例)、73.7%(118例)和60.6%(97例);CD147的表达与乳腺癌腋淋巴结受累、TNM分期和HER2过表达均呈正相关(P<0.01,P<0.05和P<0.01),与孕激素受体表达呈负相关(P<0.05);CD147蛋白阳性患者(55.9个月)无复发生存期显著低于阴性患者(46.1个月,P=0.023);CD147与MMP-2、MMP-9蛋白的表达均呈显著正相关(r=0.728和r=0.399,均P<0.01);CD147蛋白表达与TGFβ1和TGFβRⅠ表达均呈显著正相关(r=0.223,P<0.01和r=0.191,P<0.05).结论 乳腺癌组织中CD147表达状况与肿瘤侵袭转移和患者预后有密切关系;CD147的表达与MMP-2、MMP-9、TGFβⅠ和TGFβR Ⅰ表达状况关系密切.     

The Quarterly Case: Metastatic Tumor of Unknown Origin

Material from 41 patients with primary breast carcinoma and lymph node metastases at the time of primary surgical intervention was immunostained for c-erbB-2 protein, neuron-specific enolase (NSE), and estrogen receptors. Thirty of the primary breast carcinomas were of ductal type. Six were classified as infiltrating lobular carcinomas, 2 were apocrine, 1 was mucinous, and 1 was a tubular carcinoma. One tumor could not be classified as ductal or lobular by light microscopic examination alone. The number of lymph node metastases available varied from 1 to 14 per case (median, 3.9). Nine (22%) of the primary breast carcinomas (8 ductal and 1 apocrine) expressed c-erbB-2 protein and showed c-erbB-2 gene amplification; 12 expressed NSE immunoreactivity. None expressed both markers. Estrogen receptor immunoreactivity was present in 23 of the 41 cases, including 9 of the NSE-positive cases. C-erbB-2 protein-positive metastases were present in 18 cases (44%), and in 13 cases all metastases were immunostained. In 5 cases the expression of c-erbB-2 protein varied from metastasis to metastasis. NSE immunoreactivity was expressed in 10 cases, and in 3 cases with minor NSE-positive cell populations the metastatic lesions expressed c-erbB-2 protein as well. All 9 primary breast carcinomas expressing c-erbB-2 protein had lymph node metastases with c-erbB-2-immunoreactive tumor cells. Eight of the 9 c-erbB-2 protein-negative primary tumors with metastases expressing c-erbB-2 protein showed no amplification of the c-erbB-2 gene. Thus expression of c-erbB-2 protein can occur during the metastatic process, even if it seems to be missing in the primary tumor. On the other hand, if a primary breast carcinoma expresses c-erbB-2 protein, this feature seems to be present in all the tumor metastases as well.     

乳腺癌细胞基质MMP-9和TIMP-2的表达及其临床意义

目的 :研究乳腺癌组织中细胞外基质金属蛋白酶 9(MMP 9)和组织基质金属蛋白酶抑制剂 2 (TIMP 2 )的表达及其与淋巴转移和预后的相关性。方法 :通过免疫组织化学的方法检测 10 9例乳腺癌组织中MMP 9和TIMP 2表达的情况。结果 :MMP 9和TIMP 2在人乳腺癌中表达的阳性率分别为 6 6 97%和 30 2 7% ;MMP 9的表达与组织学分级、淋巴结转移呈正相关 (P <0 0 1) ,与术后生存率呈负相关 ,而TIMP 2的表达则相反。结论 :MMP 9和TIMP 2的表达与乳腺癌淋巴结转移与预后密切相关 ,可作为判断乳腺癌转移和预后的指标     

整合素αvβ6和MMP-9在胃癌中表达及其与胃癌病理生物学特征的关系

目的:探讨整合素αvβ6、MMP-9在胃癌中表达及其与胃癌病理生物学特征的关系。方法:采用EnVision免疫组化方法检测94例胃癌及癌旁胃黏膜组织中整合素αvβ6、MMP-9的表达情况,并分析两者表达与胃癌病理生物学特征的关系。结果:胃癌组织中整合素αvβ6和MMP-9阳性表达率明显高于癌旁胃黏膜组织(P<0.01)。整合素αvβ6在胃癌组织中的表达与Lauren分型、组织分化程度、是否有淋巴结转移(N分期)以及TNM分期密切相关(P<0.01),而MMP-9在胃癌组织中的表达与Lauren分型、组织分化程度、是否有淋巴结转移(N分期)、浸润深度以及TNM分期密切相关(P<0.01)。在胃癌组织中整合素αvβ6和MMP-9的表达呈正相关(r=0.672,P<0.01)。整合素αvβ6和MMP-9表达阴性患者的5年生存率明显优于整合素αvβ6和MMP-9表达阳性的患者(P<0.01)。Cox回归多因素分析表明Lauren分型、是否有淋巴结转移(N分期)、整合素αvβ6和MMP-9高表达是影响患者5年生存率的独立预后因素(P<0.05)。结论:整合素αvβ6和MMP-9的高表达与胃癌的浸润、转移密切相关;两者表达可作为判断胃癌患者预后的参考指标及治疗的靶向目标。     

Kiss-1及基质金属蛋白酶9在结肠癌组织中的表达及意义

目的检测Kiss-1及基质金属蛋白酶9(MMP-9)在结肠癌组织中的表达,探讨其临床意义。方法采用链霉菌抗生物素蛋白-过氧化酶连接(SP)法检测68例结肠癌,26例结肠腺瘤及26例正常结肠组织中Kiss-1及MMP-9的表达情况,分析其与各种临床病理参数的关系及两者表达的关联性。结果Kiss-1蛋白metastin在结肠癌组中的表达率(48.5%)明显低于结肠腺瘤组(80.8%)及正常结肠组(96.2%),并且其在结肠癌组中的表达率在不同的组织学分级、肌层浸润深度及淋巴结转移中差异有统计学意义(P均<0.05)。MMP-9在结肠癌组中的表达率(75%)明显高于结肠腺瘤组(38.5%)和正常结肠组(15.4%),其在结肠癌组中的表达率在不同的肌层浸润深度、淋巴转移中差异有统计学意义(P均<0.05)。Kiss-1蛋白metastin与MMP-9在结肠癌中的表达呈相反的趋势,有关联性(P<0.01)。结论Kiss-1蛋白metastin的表达下调和MMP-9的表达上调可能与结肠癌的浸润、转移有关。     

乳腺癌非前哨淋巴结转移的预测

目的 :预测非前哨淋巴结 (non SLN)转移 ,以筛选出转移局限于前哨淋巴结 (SLN)的乳腺癌患者。方法 :采用99mTc SC作为示踪剂 ,对 95例乳腺癌患者行前哨淋巴结活检 ,对乳腺癌非前哨淋巴结转移进行单因素和多因素分析。结果 :95例患者中成功发现 91例患者有SLN (95 8% ) ,其中 85例患者SLN能准确反映腋窝淋巴结的病理状况 (93 4% )。临床肿块大小(P =0 0 2 8)、肿瘤分级 (P =0 0 40 )和原发灶cyclinD1蛋白 (P =0 0 17)的表达与non SLN转移显著相关。而Logistic多因素分析证实 ,临床肿块大小、肿瘤分级为独立的预测非前哨淋巴结转移的因子。结论 :可根据临床病理学特征 ,筛选出乳腺癌转移只局限于前哨淋巴结的患者 ,也存在免除腋窝淋巴结清扫的可能性     

MMP-14和c-myc基因在乳腺癌组织中表达及临床意义

目的分析乳腺癌病灶组织中基质金属蛋白酶(MMP)-14和c-myc原癌基因的表达活性,并探讨其与肿瘤临床特征和生存预后的关系,为乳腺癌的发生及靶向治疗提供理论依据。方法选择经手术切除获得病理组织确诊为乳腺癌患者共90例,年龄38~78岁,平均年龄53.6岁。对每例患者分别完整切除肿瘤组织和至少距离肿瘤切缘3 cm的正常乳腺组织,以免疫组织化学法半定量检测MMP-14蛋白,荧光原位杂交技术(FISH)检测组织c-myc基因扩增阳性率,进一步比较MMP-14蛋白和c-myc基因阳性与阴性表达者在不同肿瘤临床特征(包括年龄、肿瘤直径、临床分期、病理分级、淋巴结转移)中的差异,分析MMP-14蛋白和c-myc基因表达间的相关性;随访1~5年,比较MMP-14蛋白和c-myc基因阳性与阴性表达者的无瘤生存期、复发率和总生存率的差异性。结果每例患者均至少获得1份可有效分析的癌组织和癌旁正常组织。结果发现,癌组织MMP-14蛋白和c-myc基因表达阳性率显著高于癌旁正常组织(χ^2=40.000、31.358,P<0.05)。对MMP-14蛋白和c-myc基因在不同肿瘤临床特征的样本中进行分析发现,肿瘤直径越大、临床分期越晚、病理分级越低和伴淋巴结转移者的MMP-14蛋白、c-myc基因阳性表达越明显(P<0.05),但与年龄无关(P>0.05)。MMP-14蛋白阳性表达者的c-myc基因表达阳性率高于MMP-14蛋白阴性者,而c-myc基因阳性表达者的MMP-14蛋白表达阳性率高于c-myc基因阴性者(χ^2=4.160,P<0.05)。随访发现,MMP-14蛋白和c-myc基因阳性表达患者的无瘤生存期较阴性者显著缩短(P<0.05),复发率和总生存率比较,差异无统计学意义(P>0.05)。结论MMP-14蛋白和c-myc基因可广泛存在乳腺癌病灶组织中并被稳定检测出,表达上调可能参与乳腺癌的发生机制,并且在不同的肿瘤临床特征和生存预后结局患者中可检测出差异性表达,对早期诊断乳腺癌或作为肿瘤的敏感标志物有一定的应用潜力。     

Activity of MMP-2 and MMP-9 in sera of breast cancer patients

Gelatinase A (MMP-2) and gelatinase B (MMP-9) are proteolytic enzymes involved in the process of tumor invasion, and they are considered as possible tumor markers in breast cancer patients. In this study, we examined serum activity of proMMP-2 and proMMP-9 in relation to TNM stage, tumor size, lymph node involvement, grade of differentiation of tumors, as well as steroid and Her2/neu receptor status in breast cancer patients. The activity of gelatinase in the sera of 52 patients was analyzed by SDS-PAGE zymography. The activity of proMMP-2 and proMMP-9 significantly increased with each advancing clinical stage of disease (p=0.02–0.0009) and compared to controls (p=0.015 to p<0.01). We found a positive correlation between the activity of proMMP-2 and proMMP-9 and tumor size (p=0.007; p=0.05). Patients with lymph node-positive cancer have higher proMMP-2 and proMMP-9 activity than those with node-negative cancer. ProMMP-2 and proMMP-9 activity is not associated with the expression of Her2/neu receptors, but patients with Her2/neu overexpression (3+) showed increased proMMP-2 activity. Steroid receptor score is not associated with enhanced gelatinase activity. The relationship between the increase in proMMP-2 and proMMP-9 activity in serum and tumor size and lymph node status suggests the usefulness of these enzymes as staging markers of breast cancer patients.     

KiSS-1 Expression in Human Breast Cancer

The KiSS-1 gene encodes a 145 amino acid residue peptide that is further processed to a final peptide, metastin, a ligand to a G-coupled orphan receptor (OT7T175/AXOR12). KiSS-1 has been identified as a putative human metastasis suppressor gene in melanomas and in breast cancer cell lines. This study aimed to determine the expression and distribution of KiSS-1 and its receptor in human breast cancer tissues and to identify a possible link between expression levels and patient prognosis. Frozen sections from breast cancer primary tumours (matched tumour 124 and background 33) were immuno-stained with KiSS-1 antibody. RNA was reverse transcribed and analyzed by Q-PCR (standardized using β-actin, and normalized with cytokeratin-19 levels). Levels of expression of KiSS-1 were higher in tumour compared to background tissues (3124±1262 vs 2397±1181) and significantly increased in node positive tumours compared to node negative (3637±1719 vs 2653±1994, P = 0.02). KiSS-1 expression was also increased with increasing grade and TNM status. There were no such trends with the KiSS-1 receptor. Expression of KiSS-1 was higher in patients who had died from breast cancer than those who had remained healthy (4631±3024 vs 2280±1403) whereas expression of the receptor was reduced (480±162 vs 195±134). Immunohistochemical staining showed increased expression of KiSS-1 in tumour sections. Insertion of the KiSS-1 gene into the human breast cancer cell line MDA-MB-231, resulted in cells that were significantly more motile and invasive in behaviour, with reduced adhesion to matrix, using respective assays. In conclusion, KiSS-1 expression is increased in human breast cancer, particularly in patients with aggressive tumours and with mortality. Over-expression of KiSS-1 in breast cancer cells result in more aggressive phenotype. Together, it suggests that KiSS-1 plays a role beyond the initial metastasis repressor in this cancer type.     

胃癌中SDF-1、CXCR4、MMP-2和MMP-9的表达及意义

目的研究趋化因子SDF-1及其受体CXCR4以及MMP-2和MMP-9在胃癌中的表达,探讨SDF-1对MMP-2和MMP-9表达的影响。方法应用免疫组化EnVision两步法检测109例胃癌组织中SDF-1、CXCR4、MMP-2和MMP-9的表达。结果 (1)SDF-1、CXCR4、MMP-2、MMP-9在胃癌组的表达阳性率分别为88.1%、56.9%、80.7%和83.4%,高于切缘对照组的47.8%、30.4%、43.4%和47.8%,差异有显著性(P<0.05);(2)SDF-1和CXCR4的表达在淋巴结转移组高于无转移组(P<0.05),SDF-1、MMP-9表达程度与淋巴结转移、组织学分级、浆膜侵犯、临床分期指标呈正相关(P<0.05);MMP-2、CXCR4表达程度与淋巴结转移、浆膜侵犯、临床分期呈正相关(P<0.05);(3)SDF-1与其受体CXCR4的表达及与MMP-2、MMP-9均呈正相关(P<0.05)。结论 (1)SDF-1、CXCR4、MMP-2和MMP-9的表达水平与胃癌的发生、侵袭及淋巴结转移密切相关,可作为预测胃癌淋巴结转移及预后的指标;(2)SDF-1/CXCR4轴可通过加强肿瘤细胞MMP-2和MMP-9分泌的途径促进肿瘤的浸润和转移,提示SDF-1可能是药物靶向治疗的重要靶点。     

SLP-2在胃癌组织中的表达及其预后意义

 目的：探讨红细胞膜整合蛋白SLP-2（stomatin-like protein 2）在胃癌中的表达及其与临床病理学指标及预后的关系。方法：选取中山大学肿瘤防治中心病理科有完整临床资料的胃癌手术标本190例,应用免疫组织化学方法检测胃癌中SLP-2蛋白的表达,并分析其与临床病理特征及预后的关系。结果：（1）胃癌组织中SLP-2蛋白表达的阳性率为63.2%（120/190）。SLP-2表达与胃癌浸润深度、TNM分期及淋巴结转移有关（P<0.05）,而与患者性别、年龄、肿瘤分化程度、肿瘤直径和远处转移均无关（P>0.05）;（2）Kaplan-Meier 生存曲线分析结果显示：SLP-2阳性表达患者的累积生存率明显低于阴性表达患者（P<0.01）;（3）单因素分析结果显示：SLP-2 的表达、淋巴结转移、肿瘤分化程度、肿瘤直径、TNM分期、浸润深度及远处转移均影响胃癌预后;多因素分析表明,只有肿瘤直径和TNM分期是独立的预后指标。结论：（1）SLP-2在胃腺癌组织中高表达,可能参与胃腺癌的发生发展和转移;（2）SLP-2在一定程度上影响胃癌的预后,其过度表达提示胃癌预后差。